Objective-Angiogenesis is the formation of new blood vessels through endothelial cell sprouting. This process requires the mitogen-activated protein kinases, signaling molecules that are negatively regulated by the mitogen-activated protein kinase phosphatase-1 (MKP-1). The purpose of this study was to evaluate the role of MKP-1 in neovascularization in vivo and identify associated mechanisms in endothelial cells. Approach and Results-We used murine hindlimb ischemia as a model system to evaluate the role of MKP-1 in angiogenic growth, remodeling, and arteriogenesis in vivo. Genomic deletion of MKP-1 blunted angiogenesis in the distal hindlimb and microvascular arteriogenesis in the proximal hindlimb. In vitro, endothelial MKP-1 depletion/deletion abrogated vascular endothelial growth factor-induced migration and tube formation, and reduced proliferation. These observations establish MKP-1 as a positive mediator of angiogenesis and contrast with the canonical function of MKP-1 as a mitogenactivated protein kinase phosphatase, implying an alternative mechanism for MKP-1-mediated angiogenesis. Cloning and sequencing of MKP-1-bound chromatin identified localization of MKP-1 to exonic DNA of the angiogenic chemokine fractalkine, and MKP-1 depletion reduced histone H3 serine 10 dephosphorylation on this DNA locus and blocked fractalkine expression. In vivo, MKP-1 deletion abrogated ischemia-induced fractalkine expression and macrophage and T-lymphocyte infiltration in distal hindlimbs, whereas fractalkine delivery to ischemic hindlimbs rescued the effect of MKP-1 deletion on neovascular hindlimb recovery. Conclusions-MKP-1 promoted angiogenic and arteriogenic neovascular growth, potentially through dephosphorylation of histone H3 serine 10 on coding-region DNA to control transcription of angiogenic genes, such as fractalkine. These observations reveal a novel function for MKP-1 and identify MKP-1 as a potential therapeutic target. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
A ngiogenesis, the process of endothelial cell (EC) sprouting from existing vessels to form new vessels, is essential for myriad physiological processes and pathological conditions, including development and growth, regeneration and repair, and tumor growth and metastasis. 1, 2 Despite intense study, the mechanisms underlying the activation, progression, and regulation of angiogenesis remain incompletely understood. 1 The vascular endothelial growth factor (VEGF) has been identified as one of the most potent cytokines capable of initiating and maintaining this process and has long been a target for both pro-and antiangiogenic therapies. 3, 4 Despite its potency in model systems, both delivery of VEGF, through recombinant proteins or gene therapy, and inhibition of VEGF for cancer therapy have had mixed clinical success. [4] [5] [6] Thus, elucidating the molecular and regulatory mechanisms underlying this process is essential for both therapeutic formation of new vessels that feed growing and regenerating tissues, as well as prevention of aberrant vascular growth that drives tumor size and aggression. 1, 6 One of the key mechanisms that regulates the cellular response to growth factors, cytokines, and environmental stresses is the mitogen-activated protein kinase (MAPK) signaling pathway. 7 This pathway consists of several families of primary kinase effectors, extracellular-related kinase, p38, and c-Jun N-terminal kinase. 8 These MAPK are required for vascular growth and development [9] [10] [11] [12] and positively mediate angiogenic processes in ECs, including migration, proliferation, and tube formation. [13] [14] [15] [16] [17] They are deactivated through Thr/ Tyr dephosphorylation by the nuclear phosphatase, MAPK phosphatase-1 (MKP-1; also known as DUSP1 or CL100). 18 In this study, we investigated the role of MKP-1 in angiogenic and arteriogenic neovascularization. Given the requirement of MAPK activation for vascular development and angiogenesis, we previously hypothesized that MKP-1 negatively regulates angiogenesis; surprisingly, however, we found that MKP-1 positively mediated EC migration and aortic ring sprouting in response to VEGF stimulation in vitro, 19 suggesting that MKP-1 may also have a noncanonical function that plays a positive role in neovascularization independently or concurrently with its action on MAPK.
Further recent observations from our laboratory suggested a potential effector of this putative noncanonical signaling: MKP-1-mediated chromatin modification. Using a substrate trap cysteine-to-serine (C259S) mutant of MKP-1 (CS-MKP-1), which results in stable binding of MKP-1 to its substrates, we identified MKP-1 as the only known mammalian histone H3 serine 10 (H3S10) phosphatase, which is required for VEGF-induced H3S10 dephosphorylation. 20 Here, we describe the effect of genomic deletion of MKP-1 on angiogenic and arteriogenic recovery from hindlimb ischemia in vivo and demonstrate a positive role for endothelial MKP-1 in angiogenic gene expression associated with MKP-1-mediated exonic histone H3 dephosphorylation on the angiogenic and inflammatory gene, fractalkine.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
MKP-1 knockout and littermate wild-type mice (n=11-20 per group) underwent surgical induction of hindlimb ischemia, 21, 22 and angiogenic and arteriogenic recovery were evaluated >28 days by longitudinal laser Doppler perfusion imaging ( Figure 1A and 1B). Exponential curve-fit analysis demonstrated that MKP-1 knockout mice featured significantly slower recovery when compared with wild type (τ WT =4.44±0.99 days; τ KO =13.7±4.08 days; P=0.04) but recovered to the same plateau by day 28 (P WT =0.48±0.03, P KO =0.54±0.09; P=0.58). The perfusion ratio was significantly lower in knockout limbs at days 3 and 7, and knockout mice recovered to wild-type levels by day 28.
On the basis of these observations, we selected days 7 and 28 for quantitative micro-computed tomography (CT) angiography analysis. Angiogenesis and arteriogenesis are linked in the hindlimb ischemia model because sufficient collateralization of the upper hindlimb is necessary for perfusion and angiogenesis of the lower hindlimb and sufficient capillary networks are required for arteriogenesis and collateralization. Thus, angiogenesis and collateral arteriogenesis act in concert to establish a functional vascular network in both proximal and distal parts of the ischemic limb. However, although these mechanisms of new vessel formation cannot be spatially divorced, they are dominant in different regions of the limb, as has been described previously. 23, 24 Vascular growth in the thigh occurs primarily through arteriogenesis stemming from increased wall shear stress in collateral vessels, whereas it proceeds predominantly through angiogenesis in the lower hindlimb (calf) as a result of tissue hypoxia. 23, 24 Therefore, these 2 regions of interest were selected for independent analysis. In the distal hindlimb, wild-type mice featured a biphasic recovery characterized by increased vascularity above contralateral controls at day 7 (P<0.05 versus control) and remodeling to control values by day 28 (P>0.05 versus control). In contrast, vascular parameters of knockout mice failed to exceed unoperated controls at either time point, with significantly lower vascularity when compared with ischemic wild-type limbs at day 7 and equivalent values at day 28 ( Figure 1C -1G; unoperated control values indicated by dotted lines). In the proximal hindlimb, there were no differences in vascular parameters between genotypes or between control and ischemic limbs, with the exception of connectivity at day 7, in which ischemic limbs of wild-type mice had significantly greater connectivity than the contralateral control and ischemic limbs of knockout mice ( Figure I in the online-only Data Supplement).
Because micro-CT angiography is limited by resolution to assess patent vessels of ≈20 μm in diameter, 25,25a microvascular angiogenesis and arteriogenesis were evaluated in both regions of interest by immunofluorescent staining for capillaries (EC marker BS-1 lectin) and arterioles (αSMA+, BS-1 lectin-stained vessels) at days 7, 14, and 28. In the gastrocnemius muscle of the lower hindlimb, ischemia significantly increased capillary density in wild-type mice when compared with controls ( Figure 2A and 2B). This increase was delayed in MKP-1 knockout mice, with significantly lower values at days 7 and 14 but recovery to wild-type values by day 28. In contrast, capillary density was not significantly altered by MKP-1 deletion in the soleus muscle (SM) of the upper hindlimb ( Figure 2C and 2D). Arteriole formation was not affected by MKP-1 deletion in the gastrocnemius muscle ( Figure 2E and 2F), but in the SM muscle of the upper hindlimb, arteriole density was significantly higher in wild-type mice when compared with knockout and controls at day 7 ( Figure 2G and 2H).
To evaluate the time course of MKP-1 expression in ischemic hindlimbs, SM and gastrocnemius sections of wild-type mice were immunostained for MKP-1 at days 7, 14, and 28. MKP-1 was induced by hindlimb ischemia in both regions at day 7 and decreased to control levels by day 28 ( Figure II in the online-only Data Supplement).
In vitro, MKP-1 depletion by siRNA ( Figure 3A ) completely abolished VEGF-induced human umbilical vein EC (HUVEC) migration ( Figure 3B and 3C). Similarly, mouse aortic ECs (MAEC) from knockout mice exhibited the same migratory deficit ( Figure IIIA and IIIB in the online-only Data Supplement). MKP-1 depletion significantly reduced HUVEC proliferation overall although cells remained responsive to VEGF stimulation ( Figure 3D ). MKP-1 depletion also abrogated VEGF-induced HUVEC tube formation on Matrigel with reduced length, number of nodes, and number of branches without altering cell number ( Figure 3E and 3F).
Next, to identify putative gene targets for MKP-1 regulation through chromatin interactions in HUVEC, we immunoprecipitated CS-MKP-1-bound chromatin and cloned and sequenced associated DNA. Although sequencing of vehicle-treated samples returned only pBluescript plasmid, in VEGF-treated samples, 3 independent clones were identified; these fragments overlapped one another on the proximal end of exon 3 of the angiogenic and inflammatory gene, fractalkine, also known as cx3cl1 ( Figure 4A ). To test whether MKP-1 specifically dephosphorylates H3S10 on this gene locus, we immunoprecipitated phospho-H3S10-bound chromatin in control or MKP-1-depleted HUVEC and performed real-time polymerase chain reaction for the proximal region of fractalkine exon 3. MKP-1 depletion prevented dephosphorylation of H3S10 on this gene locus at 0 and 30 minutes after VEGF treatment, returning to control levels by 90 minutes, but remained dephosphorylated at all time points in control cells ( Figure 4B ). In contrast, binding of total histone H3 to this DNA locus was not affected by MKP-1 depletion ( Figure 4C ).
Next, we evaluated fractalkine induction by VEGF in HUVEC. In cells depleted of MKP-1, VEGF-induced fractalkine expression was completely ablated at both the message ( Figure 4D ) and the protein ( Figure 4E ) levels. Similarly, To verify that MKP-1 mediated fractalkine gene regulation in vivo, we evaluated fractalkine protein expression in both gastrocnemius and SM muscles of control and ischemic hindlimbs of wild-type and MKP-1 knockout mice at days 7, 14, and 28 by immunofluorescence. Fractalkine staining colocalized with ECs in the ischemic hindlimbs of both wild-type and knockout mice ( Figure IV in the online-only Data Supplement), demonstrating that ECs in the ischemic hindlimb express fractalkine although fractalkine staining was not exclusive to ECs, consistent with its role as a soluble signaling molecule in its cleaved form. In gastrocnemius muscle of the lower hindlimb, fractalkine expression was significantly induced over control levels in ischemic limbs of wild-type, but not knockout, mice at day 7, confirming the MKP-1 dependence of fractalkine expression. Over time, expression decreased to negligible levels in both genotypes by day 28 (Figure 5A and 5B). Background Mitogen-activated protein kinase phosphatase-1 (MKP-1)-chromatin interactions and fractalkine regulation. Human umbilical vein endothelial cells (HUVECs) were transfected with substrate trap mutant CS-MKP-1 (myc-tagged) and treated 10 minutes with 50 ng/ mL VEGF or vehicle; chromatin was immunoprecipitated using an antimyc antibody, and associated DNA were cloned and sequenced. In VEGF-treated samples, 3 independent clones were identified overlapping exon 3 of the angiogenic chemokine, fractalkine, as illustrated (A). Vehicle-treated samples had no DNA binding. HUVEC depleted of MKP-1 by siRNA were treated with 50 ng/mL VEGF during a 90-minute time course, and chromatin was immunoprecipitated using antibodies against phospho-histone H3S10 (B) or H3 (C) on this DNA locus. MKP-1 depletion enriched the DNA for p-H3S10 at 0 and 30 minutes after VEGF treatment but had no effect on total H3 binding. Fractalkine mRNA (D) and protein (E) expression were induced under control conditions but completely ablated when MKP-1 was depleted. HUVEC depleted of fractalkine (F) exhibited a blunted migratory response to VEGF (G), but treatment with recombinant fractalkine rescued the migratory deficit of MKP-1-depleted cells (H). *P≤0.05, **P≤0.01. NS indicates not significant.
fractalkine levels were moderately elevated in control limbs at day 7 when compared with days 14 and 28, suggesting a systemic circulation of cytokines that resulted in contralateral induction although this was insufficient to cause inflammatory cell infiltration in distal knockout or control limbs ( Figure 5G , 5H, 5J, and 5K). This may suggest a threshold expression level necessary for inflammatory cell infiltration, which was not met in either control or knockout limbs at any time point. In SM muscle of the upper hindlimb, fractalkine expression was not significantly induced in either ischemic or control limbs of either genotype ( Figure 5C ). Although monocyte/ macrophage infiltration was significantly induced by ischemia at day 7 in SM sections, it was less robust than in gastrocnemius muscle, and there were no differences between wild-type and MKP-1 knockout mice ( Figure 5I) . T-lymphocyte staining in SM sections was minimal and exhibited no differences between genotypes ( Figure 5L ).
Next, we quantified the time course of VEGF protein expression in gastrocnemius and in SM muscles of control and ischemic hindlimbs of wild-type and MKP-1 knockout mice. In the gastrocnemius muscle, VEGF expression was induced by ischemia in wild-type mice although expression did not differ significantly from knockout levels ( Figure 5D and 5E ). There were no differences at days 14 or 28. In wild-type SM muscle, VEGF was significantly induced by hindlimb ischemia at day 7 and decreased through day 28, whereas in knockout mice VEGF expression was not elevated at day 7 but increased over time ( Figure 5F ). VEGF expression levels were lower in SM than that in gastrocnemius muscles for both genotypes.
Fractalkine is a potent chemotactic agent for inflammatory leukocytes, [25] [26] [27] so to evaluate the role of MKP-1 in the time course of inflammation, gastrocnemius and SM sections from wild-type and MKP-1 knockout mice were probed for monocytes/macrophages (CD68; Figure 5G -5I) and T-lymphocytes (CD3; Figure 5J and 5K) at 7, 14, and 28 days. In gastrocnemius muscle, monocyte/macrophage and T-lymphocyte infiltration were minimal in control limbs and in ischemic limbs of knockout mice but was significantly elevated in ischemic limbs of wild-type mice at all time points evaluated ( Figure 5G , 5H, 5J, and 5K). In contrast, in SM muscle, monocyte/macrophage infiltration was elevated at day 7 in both wild-type and knockout mice and diminished to negligible levels by day 28. T-lymphocyte staining was minimal in all groups at all time points in SM sections. Immunofluorescence specificity was demonstrated in positive and negative controls ( Figure V in the online-only Data Supplement).
Finally, to test whether delivery of recombinant fractalkine would rescue the effect of MKP-1 deletion, wild-type and MKP-1 knockout mice (n=6 per genotype) received hindlimb ischemia and were then injected intramuscularly immediately after surgery with 5-μg recombinant mouse fractalkine, divided evenly between gastrocnemius and SM muscles, as described previously in rats. 28 Although fractalkine delivery unexpectedly had no effect in wild-type mice, perfusion recovery of MKP-1 knockout mice was restored to wild-type untreated levels (data reproduced from Figure 1 in gray), with no significant differences between wild-type-untreated, wild-type-treated, or knockout-treated groups at any time point ( Figure 6A and 6B) . Exponential curve-fit analysis revealed no differences in characteristic time scales between fractalkine-treated wild-type and fractalkine-treated knockout mice (τ WT =9.29 days; τ KO =8.03 days; P=0.83). Gastrocnemius and SM muscles at day 7 after ischemia (n=3 per group) were sectioned and immunostained for capillaries ( Figure 6C ), arterioles ( Figure 6D ), fractalkine ( Figure 6E ), monocyte/macrophages ( Figure 6F ), and T-lymphocytes ( Figure 6G ). For each measure, there were no differences between wild-type or MKP-1 knockout mice.
Discussion
In this study, we evaluated the role of the nuclear phosphatase, MKP-1, in neovascularization using hindlimb ischemia as a model system to evaluate angiogenesis, arteriogenesis, and vascular remodeling. We found that MKP-1 was transiently induced by hindlimb ischemia and positively mediated neovascular growth in vivo and in vitro, in part through regulation of the angiogenic and inflammatory chemokine, fractalkine.
Hindlimb ischemia recovery can be characterized as an underdamped feedback control system with a biphasic response profile featuring an initial phase of vessel growth peaking above contralateral controls and a later phase of vessel rarefaction and remodeling in which unnecessary and inefficient vessels are pruned away without changes in functional perfusion. 29 In this study, wild-type mice followed this underdamped biphasic profile, with vascular parameters elevated above contralateral controls at day 7 and normalized by day 28. In contrast, MKP-1 knockout mice responded as an overdamped system, failing to supersede control values at any time point.
These data demonstrate a critical role for MKP-1 in the early growth phase of neovascular growth, attributable to a combination of angiogenesis and arteriogenesis. These processes can be evaluated by 3-dimensional vascular network analysis and immunostaining for both capillary and arteriole formation. MKP-1 deletion inhibited hypoxia-induced angiogenesis in the distal hindlimb but did not affect arteriole formation in this region. In the proximal hindlimb, MKP-1 knockout limbs did not show differences in capillary density but exhibited transiently reduced arteriogenesis, as measured by arteriole staining. The MKP-1-associated defect in arteriogenesis was largely limited to the microvasculature because micro-CT angiography did not detect differences in vascular network parameters besides connectivity. However, of the micro-CTbased parameters, connectivity has been shown to correlate best with functional perfusion, 21 suggesting a potential functional importance of MKP-1 in arteriogenesis. Together, these data implicate MKP-1 as an important regulator of the early response to ischemia, with downstream effects mirroring the kinetics of MKP-1 expression in the ischemic limb. These data are consistent with reports that MKP-1 is induced in ischemic tumor microenvironments 30 and is required for VEGF expression and maintenance of vascular density in hypoxia-exposed lung. 30 Importantly, the early angiogenic response is critical for prevention of irreversible myocardial necrosis in ischemic heart disease and is an indicator of functional outcome 31, 32 and mediates revival of tumor cells from dormancy, 33 highlighting the relevance of these findings beyond accelerated recovery from peripheral artery disease.
To evaluate the molecular mechanisms by which MKP-1, a negative regulator of MAPK, may serve a positive role in angiogenic function of ECs, we evaluated the effect of MKP-1 depletion/deletion on HUVEC/MAEC angiogenesis in vitro. We found that endothelial MKP-1 is required for VEGF-induced migration and tube formation and positively contributed to EC proliferation independently of VEGF. Initially, these data seem to conflict with a recent report that MKP-1 overexpression reduced EC motility and proliferation. 34 In those experiments, however, MKP-1 was expressed to supraphysiological levels, which may lead to nonphysiological outcomes. Indeed, in that report, depletion of MKP-1 reduced VEGF-stimulated proliferation, consistent with the proangiogenic role described here. These data are consistent with our previous observations that MKP-1 is required for VEGF-induced EC migration and aortic ring sprouting. 18 Together, this study implicates MKP-1 as an important regulatory molecule in angiogenesis and suggests that tight control of MKP-1 levels is required for proper EC function.
Our previous discovery that MKP-1 is an H3S10 phosphatase 19 led us to hypothesize that MKP-1 may regulate EC function through chromatin modification. Using chromatin immunoprecipitation, we identified MKP-1 association with exon 3 of the angiogenic chemokine fractalkine and found that MKP-1 dephosphorylated H3S10 on this DNA locus and was required for fractalkine induction by VEGF. This histone modification occurred in exonic DNA, immediately proximal to the stop codon, rather than in the promoter region, suggesting that MKP-1 may regulate transcriptional arrest and progression rather than initiation. These data support the hypothesis that histone tail modifications downstream of the promoter also contribute to the histone code, regulating not only transcription initiation and transcription factor recruitment but also elongation and propagation of chromatin disruption. 35 Such coding-region histone modification for gene regulation has been reported previously. For example, H3 and H4 acetylation within the coding region of the angiogenic VEGF-cofactor, CCN1 (CCN family member 1), mediate chromatin folding, and transcription. 36 In addition, H3S10 phosphorylation is required for the initiation of chromatin condensation during mitosis, 37, 38 as well as priming H3 for subsequent Lys14 acetylation, 39 a switch between permissive and repressive chromatin, 40 consistent with the observations seen here. Furthermore, H3S10 phosphorylation within the FOSL1 enhancer has been shown to trigger a Figure 6 . Rescue of mitogen-activated protein kinase phosphatase-1 (MKP-1) phenotype by recombinant fractalkine (FKN) delivery. Ischemic wild-type (WT) and MKP-1 knockout (KO) mice (n=6 per group) were intramuscularly injected immediately after surgery with 5-μg recombinant mouse fractalkine, divided evenly between gastrocnemius (GC) muscle and soleus muscle (SM). Recovery >14 days was evaluated by laser Doppler perfusion imaging (A and B) , and GC and SM muscles at day 7 (n=3 per group) were immunostained for capillaries (C), arterioles (D), fractalkine (E), monocytes/macrophages (F), and T-lymphocytes (G). Fractalkine delivery rescued the effect of MKP-1 deletion on perfusion recovery, and there were no differences in fractalkine-treated samples between genotypes for immunostained parameters.
cascade required for transcription elongation. 41 Thus, MKP-1 dephosphorylation of H3S10 may alter chromatin structure and accessibility to transcriptional machinery, allowing transcriptional progression and gene expression; however, in the absence of MKP-1, chromatin may be closed and transcription arrested. Consistent with these molecular signaling links, treatment of both HUVEC and MAEC with recombinant fractalkine rescued the migratory deficit caused by MKP-1 depletion/deletion, demonstrating the importance of this factor in MKP-1-mediated EC activation.
Given the ubiquity of histone H3, fractalkine may be representative of more general gene regulation by MKP-1. Therefore, we explored gene regulation of fractalkine as a prototype for MKP-1-mediated angiogenic gene expression. Fractalkine 42 is a multifunctional chemokine, expressed primarily by ECs, that exists in both membrane-bound and soluble forms, the latter derived by proteolytic cleavage. 25,25a It exerts its angiocrine effect through cleavage from the endothelial surface and signaling through its receptor, CX3CR1 on nearby ECs. 10, [25] [26] [27] [28] In the context of hindlimb ischemia, activated CX3CR1 induced HIF-1α (hypoxia inducible factor-1α) expression, VEGF production, and signaling through VEGF receptor 2, 28 consistent with the timecourse and MKPO-1 dependence of VEGF expression in the present study.
Fractalkine mRNA has been shown to be upregulated in ischemic hindlimbs, peaking at 1 to 3 days after surgery, and, in that study, delivery of recombinant fractalkine stimulated hindlimb recovery in a rat hindlimb ischemia model. 28 In a separate study, fractalkine induced angiogenesis in the chick chorioallantoic membrane and mouse subcutaneous pocket models with similar strength as recombinant VEGF. 41,42a In the present study, we found that MKP-1 knockout mice exhibited reduced fractalkine expression associated with deficient neovascularization, and fractalkine treatment rescued the effect of MKP-1 deletion, with no differences in functional perfusion recovery or day 7 microvascularity. However, in contrast to the rat study, exogenous fractalkine delivery failed to enhance perfusion recovery in wild-type mice, suggesting that in ischemic mice, endogenous fractalkine levels are sufficient to mediate neovascular recovery. Together, these data confirm the role of fractalkine in MKP-1-mediated neovascularization.
In addition to its angiogenic functions, fractalkine also mediates chemotaxis and firm adhesion of monocytes and T-lymphocytes to activated endothelium, [25] [26] [27] cells that play important roles in recovery from hindlimb ischemia. [43] [44] [45] [46] Consistent with these observations, we found that MKP-1 deletion dramatically reduced both monocyte/macrophage and T-lymphocyte invasion in the distal hindlimb. In the proximal hindlimb, however, inflammatory cell invasion was less than in the distal limb, and there were no differences between genotypes, which may partially explain the merely modest effect of MKP-1 deletion on arteriogenesis in that region of interest. On fractalkine delivery, there were no differences between genotypes in monocyte/macrophage or T-lymphocyte invastion in either region of interest, suggesting that this effect is mediated, at least in part, by MKP-1-regulated fractalkine expression.
Together, these data implicate a dual role for MKP-1 in neovascularization: through EC migration, proliferation, and tube formation and through inflammatory cell infiltration. This is consistent with our previous findings in the ApoE −/− background that MKP-1 mediates macrophage activation. 21 In that study, MKP-1 null mice featured decreased atherosclerotic lesion size, decreased inflammatory cytokines (interleukin-1α, tumor necrosis factor α), and increased levels of anti-inflammatory interleukin-10 in the circulation, as well as impaired macrophage spreading, migration, and tissue infiltration. 21 Mechanistically, defective extracellularrelated kinase-1/2 signaling was implicated in the reduced migration of MKP −/− and ApoE −/− macrophages through pharmacological Mek1/2 kinase inhibition. 21 Thus, MKP-1 may play dual roles in recovery from hindlimb ischemia, involving both its canonical function as a MAPK phosphatase in inflammatory cells and its chromatin-modifying function in ECs.
In addition, increasing evidence suggests that chemokine pathways, such as CCL2/CCR2 and fractalkine/CX3CR1, control imflammatory cell mobilization from the bone marrow to the bloodstream. 47, 48 For example, Cochain et al 48 showed that although the CCL2/CCR2 axis regulated recruitment of Ly6C hi monocytes to the circulation and contributed to hindlimb ischemia recovery, CX3CR1 −/− mice exhibited a reduction in only Ly6C lo monocytes and did not present a deficit in hindlimb neovascularization. Future studies will evaluate the role of MKP-1 in regulation of other chemokine pathways and MKP-1/chemokine-mediated monocyte mobilization and their role in neovascularization.
These data do not rule out the possibility that canonical MAPK deactivation may contribute to the functional effects observed here because numerous studies have verified the MAPK phosphatase activity of MKP-1 in ECs. 18, 49, 50 Indeed, we have previously shown that VEGF induction of MKP-1 is c-Jun N-terminal kinase MAPK dependent, and VEGF-induced MKP-1 regulates phosphorylation of both c-Jun N-terminal kinase and p38, but not extracellular-related kinase-1/2, in HUVEC. 18 Thus, the observations described here may result from a combination of these various MKP-1 substrates, which may explain the blunted angiogenic growth phase concurrent with decreased fractalkine expression but eventual recovery, perhaps because of prolonged MAPK activation.
Together, these data reveal a novel role for MKP-1 in angiogenic gene expression and neovascularization in vivo, identify a putative epigenetic mechanism for MKP-1-mediated gene regulation in ECs, and validate MKP-1 as a potential therapeutic target that can be activated specifically through combinatorial growth factor stimulation. 49, 51 
